Almanack Investment Partners LLC. Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Almanack Investment Partners LLC. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 31.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 664 shares of the company’s stock after selling 308 shares during the quarter. Almanack Investment Partners LLC.’s holdings in Eli Lilly and Company were worth $513,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. TFG Advisers LLC grew its stake in shares of Eli Lilly and Company by 2.3% in the 4th quarter. TFG Advisers LLC now owns 3,411 shares of the company’s stock valued at $2,633,000 after buying an additional 77 shares during the period. MWA Asset Management lifted its holdings in Eli Lilly and Company by 26.4% in the fourth quarter. MWA Asset Management now owns 335 shares of the company’s stock valued at $259,000 after acquiring an additional 70 shares during the last quarter. Vest Financial LLC grew its position in Eli Lilly and Company by 13.6% in the fourth quarter. Vest Financial LLC now owns 3,788 shares of the company’s stock worth $2,924,000 after acquiring an additional 453 shares during the period. Cidel Asset Management Inc. increased its stake in Eli Lilly and Company by 22.6% during the fourth quarter. Cidel Asset Management Inc. now owns 15,563 shares of the company’s stock worth $12,015,000 after acquiring an additional 2,874 shares during the last quarter. Finally, Conning Inc. raised its position in Eli Lilly and Company by 4.0% in the fourth quarter. Conning Inc. now owns 10,615 shares of the company’s stock valued at $8,195,000 after purchasing an additional 411 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.9 %

Shares of NYSE:LLY opened at $878.09 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The stock has a market cap of $833.58 billion, a price-to-earnings ratio of 74.99, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. The firm’s 50 day moving average price is $789.87 and its 200 day moving average price is $843.31.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, equities research analysts predict that Eli Lilly and Company will post 23.33 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.68%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is currently 51.24%.

Eli Lilly and Company announced that its board has authorized a stock repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on LLY shares. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Citigroup cut their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.